Linagliptin Stada

Linagliptin, the active ingredient in Linagliptin Stada, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is prescribed to improve glycemic control in adults with type 2 diabetes mellitus. By inhibiting the dipeptidyl peptidase‑4 enzyme, linagliptin raises endogenous incretin levels, which enhances insulin secretion after meals and suppresses glucagon release, helping to lower blood glucose.

GNH USA supplies Linagliptin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide through reliable logistics and quality assurance.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

- Monotherapy in type 2 diabetes mellitus: Improves fasting and post‑prandial blood glucose levels. - Combination therapy with metformin or other antidiabetics: Enhances overall glycemic control when added to existing regimens. - Adjunct to lifestyle modification: Supports blood glucose management when diet and exercise alone are insufficient.

Linagliptin may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient head pain. - Dizziness: sensation of light‑headedness. - Gastrointestinal discomfort: nausea, abdominal pain or diarrhea.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Bullous pemphigoid: rare skin blistering disorder.

When prescribing linagliptin, clinicians should consider several precautionary measures to ensure safe use.

- Renal impairment: evaluate kidney function; dose adjustment is generally not required but monitor. - Hepatic impairment: use with caution and monitor liver enzymes. - Cardiovascular disease: assess risk, especially in patients with heart failure. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Concomitant sulfonylureas or insulin: increased risk of hypoglycaemia; monitor glucose. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Linagliptin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Rifampin or other enzyme inducers: may reduce linagliptin effectiveness.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: heightened hypoglycaemia risk; adjust dose as needed. - Diuretics: may affect blood glucose control; monitor levels. - Warfarin: potential alteration of INR; check coagulation parameters regularly.